ArticleInvestigational new drugs2013

ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.

Maria Ait-Tihyaty et al.PubMed ↗Publisher ↗

No numbers read from the abstract.